Comorbidity patterns and predictive factors in polycystic ovary syndrome: a cross-sectional study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252328Keywords:
Depression, Hypertension, LH/FSH ratio, Metabolic syndrome, Polycystic ovary syndrome, Rotterdam criteria, Type 2 diabetes mellitusAbstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age and is often associated with multiple metabolic and medical co-morbidities. Understanding the influence of demographic and laboratory parameters can aid in early identification and management. study aimed to evaluate the prevalence of medical co-morbidities in women diagnosed with PCOS and assess the impact of demographic and laboratory findings on these co-morbidities.
Methods: A cross-sectional study was conducted on 393 women diagnosed with PCOS based on the Rotterdam criteria. Data on age, body mass index (BMI), menstrual history, and family history were collected. Laboratory evaluations included fasting glucose, insulin levels, lipid profile, and hormonal assays (LH, FSH, testosterone. Statistical analyses assessed associations between variables using chi-square and logistic regression.
Results: Among 94 participants comorbid conditions, metabolic syndrome was identified in 27.65% of participants, while type 2 diabetes mellitus (T2DM) and hypertension were present in 14.89% and19.14%respectively. Mental health co-morbidities were also notable, with depression affecting18.05% and anxiety seen in 17.02% of the cohort higher BMI and elevated testosterone levels were significantly associated with metabolic abnormalities (p<0.05). Younger age at diagnosis and higher LH/FSH ratio were predictive of certain co-morbidities.
Conclusions: Women with PCOS are at high risk for multiple medical co-morbidities, with demographic and laboratory parameters showing significant associations. Early identification of high-risk profiles can facilitate timely intervention and improve long-term outcomes.
Metrics
References
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7. DOI: https://doi.org/10.1093/humrep/deh098
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-18. DOI: https://doi.org/10.1093/humrep/dey256
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. DOI: https://doi.org/10.1210/edrv.18.6.0318
March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51. DOI: https://doi.org/10.1093/humrep/dep399
Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575-92. DOI: https://doi.org/10.1093/humupd/dmv029
Moran LJ, Misso ML, Wild RA, Norman RJ. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. Obstet Gynecol. 2015;125(6):1397-406. DOI: https://doi.org/10.1097/AOG.0000000000000852
Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-91. DOI: https://doi.org/10.1093/humrep/dex044
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: https://doi.org/10.1210/jc.2003-032046
Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13. DOI: https://doi.org/10.2147/CLEP.S37559
Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687-708. DOI: https://doi.org/10.1093/humupd/dmw025
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92. DOI: https://doi.org/10.1210/jc.2013-2350
Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19-26. DOI: https://doi.org/10.1385/ENDO:30:1:19
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31. DOI: https://doi.org/10.1038/nrendo.2010.217
Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity. 2013;21(8):1526-32. DOI: https://doi.org/10.1002/oby.20213
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38.e25. DOI: https://doi.org/10.1016/j.fertnstert.2011.09.024
Downloads
Published
How to Cite
Issue
Section
